Ligand Pharmaceuticals (LGND) has experienced a roughly 10% decline since its last 'Buy' rating, but remains viewed as a reliable midcap pharmaceutical company. The focus is on its key royalty-producing assets, which support a high-growth business model centered on royalty aggregation. The investment thesis highlights Ligand's consistent strong execution in this model, suggesting a bright future despite recent share price weakness. The article reflects the author's positive long-term outlook based on extensive research and experience in healthcare stocks.
Ligand Pharmaceuticals and its biotech peers provide context for health-sector trading on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Sep 18, 2026 18:41 WIB: Among 92 priced US health-sector stocks, 39 rose and 42 fell today. AbCellera Biologics Inc (ABCL) gained 1.57% to USD 12.93 with a typical hold time of 40 days, Adaptive Biotechnologies Corp (ADPT) rose 1.54% to USD 28.99 held for 36 days on average, and Twist Bioscience Corp (TWST) increased 1.51% to USD 157.75 with a shorter hold time of 28 days. Pluang order activity showed a slight sell bias for ABCL and a balanced buy-sell split for ADPT and TWST.
Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...
Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...
Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...
Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...
Barclays lowered its price target for Lennar Corporation to $70 from a higher level, citing a 52% drop in Q3 net earnings to $284 million and an 8.6% revenue decline to $8.05 billion. The homebuilder faces headwinds from rising mortgage rates and wea...
